Skip to main content

Table 3 Univariate analysis of factors associated with 28-day mortality

From: Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case–control study

Variable Number (%) of patients Univariate analysis
Alive (n = 84) Deceased (n = 60) p value OR (95% CI)
Demographics and comorbidities
 Age (years) 57.7 ± 15 61.7 ± 10 0.08 1.02 (0.99–1.05)
 Males 58 (69.1) 35 (58.3) 0.19 0.63 (0.31–1.25)
 CHF 24 (28.6) 21 (35) 0.41 1.34 (0.66–2.74)
 COPD 14 (16.7) 9 (15) 0.79 0.88 (0.35–2.2)
 CRF 8 (9.5) 7 (11.7) 0.68 1.25 (0.43–3.67)
 Diabetes 25 (29.8) 23 (38.3) 0.28 1.47 (0.73–2.95)
 CLD 8 (9.5) 10 (16.7) 0.21 1.9 (0.7–5.14)
 Neoplasm 7 (8.3) 7 (11.7) 0.51 1.48 (0.48–4.38)
 Immunosuppressive status 27 (32.1) 18 (30) 0.78 0.9 (0.44–1.85)
 ICU stay before infection (days), median (IQR) 8.5 (1–21) 8 (1–23) 0.69 1 (0.98–1.01)
 Duration of MV before infection (days), median (IQR) 6 (1–13.5) 5.5 (0.5–15) 0.79 1.01 (0.98–1.03)
 Duration of vasopressors before infection (days), median (IQR) 2 (0–7.5) 2 (0–7) 0.68 0.99 (0.97–1.02)
Presenting features, type of infection, and therapy
 Medical admission 45 (53.6) 39 (65) 0.17 1.61 (0.81–3.18)
 Surgical admission 29 (34.5) 15 (25) 0.22 0.63 (0.3–1.32)
 Trauma admission 10 (11.9) 6 (10) 0.72 0.82 (0.28–2.4)
 SAPS II score, median (IQR) 39 (34–50) 55 (45.5–63) <0.01 1.07 (1.04–1.08)
 SOFA score on occurrence of infection, median (IQR) 8 (5–9) 9 (8–11) <0.01 1.36 (1.17–1.57)
 SS on occurrence of infection 42 (50) 37 (61.7) 0.17 1.6 (0.82–3.16)
 ARDS on occurrence of infection 21 (25) 20 (33.3) 0.28 1.5 (0.72–3.11)
 CRRT on occurrence of infection 22 (26.2) 24 (40) 0.08 1.88 (0.92–3.82)
 PCT on occurrence of infection (ng/ml), median (interval) 3.4 (0.71–7.5) 4.3 (2.3–8.6) 0.43 1 (0.99–1.01)
Type of infection and therapy
 Pneumonia 41 (48.8) 33 (55) 0.46 1.28 (0.66–2.49)
 IAI 14 (16.7) 5 (8.3) 0.15 0.45 (0.15–1.34)
 SSTI 8 (9.5) 4 (6.7) 0.55 0.67 (0.19–2.37)
 UTI 6 (7.1) 6 (10) 0.54 1.44 (0.44–4.72)
 CVC BSI 11 (13.1) 7 (11.7) 0.8 0.88 (0.32–2.41)
 Primary BSI 9 (10.7) 7 (11.7) 0.86 1.1 (0.39–3.14)
 Secondary BSI 30 (35.7) 19 (31.7) 0.61 0.83 (0.41–1.69)
 Polymicrobial infection 8 (9.5) 15 (25) 0.01 3.17 (1.25–8.06)
 Double carbapenem therapy 34 (40.5) 14 (23.3) 0.03 0.45 (0.21–0.94)
 IIAT 26 (30.9) 27 (45) 0.08 1.82 (0.92–3.63)
 Combination targeted therapy 48 (57.1) 39 (65) 0.34 1.39 (0.7–2.76)
 Duration of active treatment (days), median (IQR) 14 (8–18.5) 10 (8–14.5 0.13 0.96 (0.93–1.01)
  1. Data presented as N (%), unless otherwise indicated. Bold data are significant
  2. OR odds ratio, IQR interquartile range, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, MV mechanical ventilation, SS septic shock, ARDS acute respiratory distress syndrome, CRRT continuous renal replacement therapy, PCT procalcitonin, CHF chronic heart failure, COPD chronic obstructive pulmonary disease, CRF chronic renal failure, CLD chronic liver disease, IAI intra-abdominal infection, SSTI skin and soft tissue infection, UTI urinary tract infection, CVC central vascular catheter, BSI bloodstream infection, IIAT initial inappropriate antimicrobial therapy